XstalBio Introduces CentuRecon
CentuRecon enables dry formulations of therapeutic proteins to quickly be prepared for injection at high concentration.
CentuRecon, a patented reconstitution technology, decreases the preparation time of high concentration protein solutions from dry powder formulations and makes delivery faster and safer, according to the company. CentuRecon enables dry formulations of therapeutic proteins to quickly be prepared for injection at high concentration and produces foam-free solutions that maximize the deliverable dose. CentuRecon is compatible with standard lyophilized formulations and diluents and with normal vials, cartridges, or dual-chamber syringes. It can be used for very high concentration and/or viscous solutions that may need to be delivered with injection devices.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
